Roundtable
Roundtable
Advertisement
Thomas Powles, MBBS, MRCP, MDRoundtable | November 28, 2023
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
View More
Thomas Powles, MBBS, MRCP, MDRoundtable | November 28, 2023
The panel shared their thoughts on the EV-302 study.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 28, 2023
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Michael Morris, MDRoundtable | November 16, 2023
The panel shares insights on future advancements in the field.
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel talks "pearls of wisdom" with radioligand therapy.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
Brian Rini, MD, FASCORoundtable | November 14, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
Brian Rini, MD, FASCORoundtable | November 14, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
Advertisement
Advertisement
Advertisement